We Understand the Value of Strong Collaborations

Poxel has built a solid foundation in the field of metabolic diseases, both validated through significant collaborations with strong partners in the industry and academia. We are committed to maximizing the therapeutic and commercial potential of our pipeline. By combining our strong internal clinical development expertise in metabolic diseases with external partners, we can create powerful synergies and advance our goal to ultimately provide better treatment options for patients.

Our Industry Collaborators

  • Sumitomo Pharma
  • DeuteRx LLC
  • Enyo Pharma
  • Merck Serono

We have a strategic development and commercialization agreement with Sumitomo Pharma for the development and commercialization of Imeglimin in Japan, China and 11 other East and Southeast Asian countries. In Japan, TWYMEEG® (Imeglimin) was approved in June 2021 for the treatment of type 2 diabetes, and Sumitomo Pharma has launched TWYMEEG® in September 2021. In China, South Korea, Taiwan and nine other East and Southeast Asian countries (Indonesia, Vietnam, Thailand, Malaysia, the Philippines, Singapore, Myanmar, Cambodia, and Laos), Sumitomo Pharma will be solely responsible for the development and commercialization of Imeglimin.

We have regained full rights for Imeglimin in the U.S., Europe, and other countries worldwide that are not covered under the Sumitomo Pharma agreement and are considering opportunities to leverage the Imeglimin data package in specific territories, including those resulting from inbound interest.

Through an agreement with DeuteRx LLC, we acquired exclusive worldwide rights to PXL065, which has successfully completed Phase 1 and Phase 2 development for the treatment of NASH. As part of the agreement with DeuteRx, we also acquired a portfolio of additional deuterated drug candidates for metabolic, specialty and rare diseases.

We have a licensing agreement with Enyo Pharma SA for our FXR (farnesoid X receptor) agonist. Enyo Pharma SA has completed a Phase 1 study and in July 2021, announced positive results for Vonafexor (EYP001) in a Phase 2a study in NASH patients over 12 weeks and topline interim results from two ongoing Phase 2a studies in chronic hepatitis B patients.

Our Academic Collaborators

  • Université de Rouen UMR INSERM 1096, France
  • Universidad Pablo de Olavide – Centro Andaluz de Biologia del Desarrollo (CABD), Spain

We collaborate on an ongoing basis with academic leaders in metabolic disease, cardiovascular disease and mitochondrial dysfunction.

Interested in Collaborating with Us?

We'd love to hear from you and discuss partnership opportunities.